Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma
Ian Judson(Royal Marsden Hospital), John Radford(The Christie Hospital), Martin Harris(The Christie Hospital), Jean‐Yves Blay(Centre Léon Bérard), Q. van Hoesel(Radboud University Nijmegen), Axel Le Cesne(Institut Gustave Roussy), A.T. van Oosterom(Universitair Ziekenhuis Leuven), M. Clemons(The Christie Hospital), Claus Kamby(Copenhagen University Hospital), C. Hermans(European Organisation for Research and Treatment of Cancer), J Whittaker, Eugenio Donato Di Paola(European Organisation for Research and Treatment of Cancer), Jaco J. Verweij, Søren Nielsen(Aarhus Municipality)
Cited by 390
Abstract
Related Papers
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project|New England Journal of Medicine|1993|5k
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al.|Journal of Clinical Oncology|1999|569